Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Endovascular Therapy in Acute Stroke Still Being Discussed

Original title: Mechanical Recanalization with Flow Restoration in Acute Ischemic Stroke. The Mechanical Recanalization with Flow Restoration in Acute Ischemic Stroke (ReFlow) Study. Reference: Christian Roth et al. J Am Coll Cardiol Intv 2013. Article in press.

The intravenous tissue-type plasminogen activator (tPA) has proved to reduce morbidity and mortality in patients with acute ischemic stroke. In the sub group of acute stroke patients with an intracranial large vessel occlusion, thrombolysis has favorable results (modified Rankin scale ≤2) only in 15 to 25% of cases. These patients could benefit from an additional mechanical like procedure; however there is no evidence to support this.

The recently described mechanical recanalization with the help of a stent-like device has promising results both technical and clinical, and this prospective study sought to assess the feasibility and safety of the described technique. Eligible patients were those admitted within 6 hours of stroke symptom onset with a >10 NIHSS (National Institutes of Health Stroke Scale) and an angiotomography to discard hemorrhage and prove a larger intracranial vessel occlusion. Within a 4.5 hr window, tPA was indicated and patient was sent to catheterization. The primary endpoint of the study was the clinical outcome rated with the modified Rankin Scale after 90 days, considering a ≤2 score as good clinical outcome. 

Safety end point was intracranial hemorrhage complicating neurological status to 4 points in the NIHSS scale and all cause mortality. Between 2010 and 2011, forty patients presenting within 6 h from stroke symptom onset were enrolled. Mechanical recanalization was performed using a Solitaire FR revascularization device (ev3, Irvine, California). 80% were admitted within 3 hrs of symptom onset and the remaining 20% within 4.5 hours. At 90 days, 60% presented a modified Rankin score of ≤2. Hemorrhage transformation was observed in 4 patients but only one 80% were admitted within 3 hrs of symptom onset and the remaining 20% within 4.5 hours. At 90 days, 60% presented a modified Rankin score of ≤2. Hemorrhage transformation was observed in 4 patients but only one associated with a 4 point complication in the NIHSS scale was considered symptomatic,. All cause death rate was 12.5%. Successful recanalization of the target vessel was achieved in 95% of the patients.

Conclusion: 

The ReFlow study shows that mechanical recanalization with flow restoration is highly effective in stroke patients with a large intracranial vessel occlusion presenting within 4.5 h after symptom onset. A randomized study is required to compare this device associated with tPA vs. tPA alone.

Editorial Comment: 

There is plenty of information on the endovascular treatment of acute ischemic stroke and, in general, outcomes have been neutral. In this work, very good outcomes were observed; however, the absence of a control group hinders a deeper analysis. The swift treatment (80% within 3 hs and all within 4.5 hs) is a limitation that reduces external validation; on the other hand, it shows us that it is possible to be within the time guideline recommendations when there is a trained team to manage stroke.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...